Zydus Lifesciences stock faces resistance at ₹920 and ₹940, with a downtrend likely to continue despite recent recovery.

The uptick in Zydus Life share price came after the company announced that it has received final approval from the USFDA to ...

The pharma industry registered a 7.5% value growth year-on-year for the month of February, with sales of ₹18,781 crore, ...

Zydus Lifesciences shares rose 7% following USFDA's final approval to market Dasatinib tablets across multiple strengths. The ...

Zydus Lifesciences has launched VaxiFlu-4, India’s first quadrivalent flu vaccine to offer better protection against ...

Zydus Lifesciences is developing a combination vaccine targeting shigellosis and typhoid, with support from the Gates ...

Zydus Lifesciences on Tuesday said it will undertake development of a combination vaccine against shigellosis and typhoid.

Zydus Lifesciences Ltd on Wednesday (March 5) said it has received final approval from the United States Food and Drug ...

Dasatinib is the generic version of Sprycel® tablets, a medication widely used for treating Ph+, chronic myeloid leukemia ...

The company launched ANVIMO (Letermovir), a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic stem cell transplant (HSCT) and kidney transplant patients. ANVIMO will ...

Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone ...

Indian pharmaceutical companies may have units abroad as part of 'distributed manufacturing' across various locations, ...